Keywords
gene therapy
CRISPR-Cas9
CAR-T cell therapy
precision oncology
How to Cite
Abstract
The convergence of personalized medicine and gene therapy represents one of the most transformative developments in modern healthcare. This narrative review explores the evolution, current applications, and future prospects of precision-based genetic interventions. From the foundational Human Genome Project to the revolutionary CRISPR-Cas9 gene editing technology and FDA-approved CAR-T cell therapies, we examine how molecular profiling and genetic modification are reshaping therapeutic paradigms. The integration of artificial intelligence, advanced delivery systems, and biomarker-driven approaches has accelerated the translation of genomic discoveries into clinical practice. This article synthesizes recent advances (2020-2025) in gene therapy applications for oncology, rare genetic disorders, and infectious diseases, while addressing critical challenges including delivery efficiency, immune responses, ethical considerations, and accessibility. The evidence suggests that personalized gene therapy is transitioning from experimental intervention to standard-of-care treatment, with market projections indicating exponential growth through 2030.
References
1. Youssef E, Fletcher B, Palmer D. Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology. Frontiers in Medicine. 2025;12:1527600. doi:10.3389/fmed.2024.1527600
2. Park H, Yu S, Koo T. Gene editing in cancer therapy: Overcoming drug resistance and enhancing precision medicine. Cancer Gene Therapy. 2025;32(1):1-15. doi:10.1038/s41417-025-00959-9
3. Boretti A. The transformative potential of AI-driven CRISPR-Cas9 genome editing to enhance CAR T-cell therapy. Computers in Biology and Medicine. 2024;168:107928. doi:10.1016/j.compbiomed.2024.107928
4. Tao R, Han X, Bai X, et al. Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology. Frontiers in Immunology. 2024;15:1354825. doi:10.3389/fimmu.2024.1354825
5. Amiri M, Moaveni AK, Majidi Zolbin M, et al. Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR/Cas9. Frontiers in Immunology. 2024;15:1462697. doi:10.3389/fimmu.2024.1462697
6. Hasanzadeh A, Ebadati A, Dastanpour L, et al. Applications of innovation technologies for personalized cancer medicine: stem cells and gene-editing tools. ACS Pharmacology & Translational Science. 2023;6(4):512-528. doi:10.1021/acsptsci.3c00102
7. Abdoli Shadbad M, Hemmat N. A systematic review on PD-1 blockade and PD-1 gene-editing of CAR-T cells for glioma therapy: from deciphering to personalized medicine. Frontiers in Immunology. 2022;13:788211. doi:10.3389/fimmu.2021.788211
8. Dimitri A, Herbst F, Fraietta JA. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Molecular Cancer. 2022;21(1):35. doi:10.1186/s12943-022-01559-z
9. Dai X, Blancafort P, Wang P, et al. Innovative Precision Gene‐Editing Tools in Personalized Cancer Medicine. Advanced Science. 2020;7(23):1902552. doi:10.1002/advs.201902552
10. U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products. Available at: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products. Accessed April 2025.
This work is licensed under a Creative Commons Attribution 4.0 International License.
